No. |
DrugBank |
薬物名(臨床試験情報から抽出) |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 | Acetate | 76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
2 | Acetylsalicylic acid | 2件: Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; | D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
3 | Ataluren | 9件: Ataluren; Ataluren (ptc124); Ataluren (ptc124®); Ataluren 1000 mg; Ataluren 1000mg; Ataluren 125 mg; Ataluren 125mg; Ataluren 250 mg; Ataluren 250mg; | D09323 |
- |
- |
6件: 19, 113, 140, 246, 299, 329 |
4 | Bisoprolol | 2件: Bisoprolol; Bisoprolol fumarate; | D00634 D02342 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 67, 86, 113 |
5 | Botulinum toxin type A | 3件: Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
6 | Calcifediol | 1件: Calcifediol; | D00122 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
2件: 113, 299 |
7 | Canakinumab | 7件: Canakinumab; Canakinumab (acz885); Canakinumab (company code: acz885d); Canakinumab (investigational); Canakinumab (proposed); Canakinumab (who approval pending); Canakinumab injection [ilaris]; | D09315 |
1件: IL1B |
40件: AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
9件: 46, 56, 84, 106, 107, 108, 113, 266, 269 |
8 | Capsaicin | 4件: Capsaicin; Capsaicin challenge; Capsaicin vapor; Qutenza (8% capsaicin); | D00250 |
1件: TRPV1 |
2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
6件: 2, 6, 19, 86, 113, 226 |
9 | Carvedilol | 2件: Carvedilol; Spironolactone captopril carvedilol; | D00255 D03415 |
5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2 |
12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
4件: 6, 57, 86, 113 |
10 | Casimersen | 1件: Casimersen; | - |
- |
- |
1件: 113 |
11 | Ciclosporin | 4件: Aerolised liposomal ciclosporin a; Ciclosporin; Ciclosporin (ciclosporinium); Ciclosporin a; | D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
44件: 11, 14, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 113, 162, 164, 222, 223, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
12 | Creatine | 4件: Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
13 | Date | 1件: Date; | - |
- |
- |
3件: 6, 88, 113 |
14 | Deflazacort | 1件: Deflazacort; | D03671 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 30, 113 |
15 | Dexmedetomidine | 8件: Dexmedetomidine; Dexmedetomidine 1; Dexmedetomidine 2; Dexmedetomidine 3; Dexmedetomidine and fentanyl; Dexmedetomidine group; Dexmedetomidine hydrochloride; Dexmedetomidine hydrochloride infusion; | D00514 D01205 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
11件: 2, 4, 6, 21, 34, 70, 113, 212, 215, 226, 280 |
16 | Domagrozumab | - | D11047 |
1件: MSTN |
1件: Cytokine-cytokine receptor interaction |
1件: 113 |
17 | Drisapersen | 2件: Drisapersen; Drisapersen sodium; | D10114 |
1件: DMD |
4件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), Viral myocarditis |
1件: 113 |
18 | Edasalonexent | 1件: Edasalonexent; | - |
- |
- |
1件: 113 |
19 | Enalapril | 4件: Enalapril; Enalapril and other angiotensin converting enzyme inhibitors; Enalapril maleate; Enalapril valsartan methylprednisone; | D00621 D07892 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
4件: 19, 46, 66, 113 |
20 | Epicatechin | 3件: (+)- epicatechin; (-)-epicatechin; Epicatechin; | - |
- |
- |
2件: 86, 113 |
21 | Epigallocatechin | 5件: Coconut oil and epigallocatechin gallate; Epigallocatechin; Epigallocatechin gallate; Epigallocatechin-3-gallate (egcg); Epigallocatechin-gallate; | - |
- |
- |
4件: 13, 28, 85, 113 |
22 | Epigallocatechin gallate | 2件: Coconut oil and epigallocatechin gallate; Epigallocatechin gallate; | - |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
23 | Eplerenone | 1件: Eplerenone; | D01115 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
3件: 75, 113, 215 |
24 | Eteplirsen | 2件: Avi-4658 (eteplirsen); Eteplirsen; | D09900 |
1件: DMD |
4件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), Viral myocarditis |
1件: 113 |
25 | Ethanol | 7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068 D02798 D04855 D06542 |
- |
- |
49件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
26 | Ezutromid | 1件: Ezutromid; | - |
- |
- |
1件: 113 |
27 | Filgrastim | 6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
28 | Gentamicin | 4件: Gentamicin; Gentamicin infusions twice a week for six months; Gentamicin sulfate; Gentamicin sulfate, injectable; | D01063 D08013 |
- |
- |
3件: 36, 113, 299 |
29 | Givinostat | 3件: Givinostat; Givinostat (hydrochloride monohydrate); Givinostat (idrocloruro monoidrato); | - |
- |
- |
1件: 113 |
30 | Guanidine | 2件: Guanidine; N(4,5bis methanesulfonyl2methylbenzoyl) guanidine hydrochloride monohydrate; | D02437 |
- |
- |
1件: 113 |
31 | Ibuprofen | 5件: Ibuprofen; Ibuprofen 200mg; Ibuprofen pch tablet 600mg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; | D00126 D01122 D04490 D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
32 | Idebenone | 2件: Idebenone; Idebenone 150 mg film-coated tablets; | D01750 |
- |
- |
4件: 6, 13, 113, 302 |
33 | Ifetroban | 2件: Ifetroban; Oral ifetroban; | D04500 |
1件: TBXA2R |
3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation |
3件: 51, 86, 113 |
34 | Isosorbide | 6件: Isosorbide; Isosorbide dinitrate; Isosorbide dinitrate 20 mg; Isosorbide dinitrate 40 mg; Isosorbide dinitrate 60 mg; Isosorbide dinitrate 80 mg; | D00347 |
- |
- |
1件: 113 |
35 | Isosorbide Mononitrate | - | D00630 |
- |
- |
1件: 113 |
36 | Isosorbide dinitrate | 5件: Isosorbide dinitrate; Isosorbide dinitrate 20 mg; Isosorbide dinitrate 40 mg; Isosorbide dinitrate 60 mg; Isosorbide dinitrate 80 mg; | D00516 |
- |
- |
1件: 113 |
37 | Isoxaflutole | - | - |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
38 | Ketamine | 3件: Ketamine; S-ketamine; S-ketamine & midazolam; | D00711 D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
6件: 6, 13, 70, 113, 156, 215 |
39 | L-Arginine | 3件: L-arginine; Ng-monomethyl-l-arginine; Ng-monomethyl-l-arginine (drug); | D02982 |
- |
- |
5件: 67, 78, 113, 251, 299 |
40 | L-Citrulline | 5件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; L-citrulline; L-citrulline and metformin & l-citrulline; L-citrulline malate; Metformin and metformin & l-citrulline; | D07706 |
- |
- |
2件: 86, 113 |
41 | L-Glutamine | 1件: L-glutamine; | D00015 |
- |
- |
6件: 87, 96, 97, 113, 245, 299 |
42 | Lisinopril | 3件: Coenzyme q10 and lisinopril; Lisinopril; Lisinopril, losartan, and atorvastatin; | D00362 D08131 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
5件: 46, 66, 67, 113, 222 |
43 | Lonafarnib | 2件: Lonafarnib; Lonafarnib, zoledronic acid, and pravastatin; | D04768 |
2件: FNTA, FNTB |
1件: Terpenoid backbone biosynthesis |
2件: 113, 333 |
44 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357 D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
45 | Losmapimod | 1件: Losmapimod; | D09639 |
4件: MAPK11, MAPK12, MAPK13, MAPK14 |
53件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Amyotrophic lateral sclerosis (ALS), C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease (American trypanosomiasis), Dopaminergic synapse, Endocrine resistance, Epithelial cell signaling in Helicobacter pylori infection, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hepatitis B, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Leukocyte transendothelial migration, MAPK signaling pathway, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Oocyte meiosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathogenic Escherichia coli infection, Pertussis, Platelet activation, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rap1 signaling pathway, Relaxin signaling pathway, Retrograde endocannabinoid signaling, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Thermogenesis, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Yersinia infection |
2件: 113, 222 |
46 | MYO-029 | 1件: Myo-029; | - |
- |
- |
1件: 113 |
47 | Mecasermin rinfabate | - | D04870 |
2件: GHR, IGF1R |
33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway |
1件: 113 |
48 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944 D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
49 | Methylphenidate | 11件: D-methylphenidate; Methylphenidate; Methylphenidate (mpd); Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylphenidate, fluoxetin, risperidone; | D01296 D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
50 | Metoprolol | 6件: Metoprolol; Metoprolol succinate; Metoprolol succinate + doxazosin; Metoprolol tartrate 50 mg; Metoprolol tartrate oral tablet; Tesofensine/metoprolol; | D00601 D02358 D05011 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
7件: 17, 57, 58, 66, 113, 193, 226 |
51 | Mexiletine | 1件: Mexiletine; | D00639 D08215 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
5件: 1, 2, 10, 113, 114 |
52 | Nebivolol | 2件: Nebivolol; Nebivolol 5 mg; | D05127 |
1件: ADRB1 |
10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
3件: 17, 113, 167 |
53 | Nitrate | 5件: Gallium nitrate; Nitrate; Pilocarpine nitrate 5%; Sodium nitrate; Sodium nitrate - double dose; | D02313 |
- |
- |
3件: 58, 113, 299 |
54 | Omigapil | 1件: Omigapil; | - |
- |
- |
1件: 113 |
55 | Oxatomide | 2件: Oxatomide; Oxatomide (tinset); | D01773 |
1件: ALOX5 |
6件: Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis |
1件: 113 |
56 | Pamrevlumab | 2件: Pamrevlumab; Pamrevlumab (fg-3019); | D10969 |
1件: CCN2 |
2件: Apelin signaling pathway, Hippo signaling pathway |
2件: 85, 113 |
57 | Pemirolast | 1件: Pemirolast; | D01088 D07476 |
- |
- |
1件: 113 |
58 | Pentoxifylline | 1件: Pentoxifylline; | D00501 |
- |
- |
10件: 26, 56, 84, 93, 96, 113, 220, 222, 296, 298 |
59 | Prasterone | 2件: Prasterone; Prasterone (gl701); | D08409 |
3件: AR, ESR1, ESR2 |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
6件: 49, 53, 83, 86, 96, 113 |
60 | Prednisolone | 46件: Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroid (prednisolone); Corticosteroid treatment (methylprednisolone or prednisolone); Corticosteroids (prednisone or prednisolone); Etanercept, methotrexate, prednisolone; Glucocorticoid (prednisone or prednisolone); Intravenous methyl prednisolone; Long-circulating liposomal prednisolone; Low dose prednisolone; Medium dose prednisolone; Methotrexate - etanercept - prednisolone arm; Methyl prednisolone; Methylprednisolone or prednisolone; Oral prednisolone; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Peg-liposomal prednisolone sodium phosphate; Prednisolone; Prednisolone & dipyridamole; Prednisolone + mabthera; Prednisolone 1mg tablets; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone 5mg tablet; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisolone and taper; Prednisolone sodium metasulphobenzoate; Prednisolone sodium phosphate; Prednisolone sodium succinate; Prednisolone tablets b.p. 5mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Prednisone or prednisolone; Prednisone/prednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; | D00472 D00980 D00981 D00982 D01239 D01998 D02156 D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
61 | Prednisone | 57件: 0 mg prednisone; 5 mg prednisone; 5-aminosalicylic acid(5-asa) and/or prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine/prednisone; Chinese herb prescription granule plus prednisone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Glucocorticoid (prednisone or prednisolone); Granulocyte-colony stimulating factor (g-csf) and prednisone; Hormone (prednisone); Hydroxychloroquine + prednisone; Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Oral prednisone; Oral prednisone 5mg; Over encapsulated prednisone; Prednisone; Prednisone (and methylprednisolone); Prednisone + inhibace/cozaar; Prednisone - azathioprine; Prednisone 0,5 mg/kg orally on alternate days; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Prednisone acetate; Prednisone acetate tablets; Prednisone alone; Prednisone and cyclophosphamide; Prednisone and mycophenolate mofetil; Prednisone and ustekinumab treatment; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone capsules; Prednisone discontinuation; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Prednisone, cyclophosphamide; Prednisone, fk506, mmf; Prednisone, methylprednisolone,cyclophosphamides; Prednisone/prednisolone; Rayos (delayed-release prednisone); Sotatercept with prednisone boost; Tacrolimus combined with prednisone; Thalidomide, cyclophosphamide and prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); | D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
62 | Ramipril | 1件: Ramipril; | D00421 |
1件: ACE |
4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system |
7件: 46, 49, 66, 67, 113, 218, 257 |
63 | Ranolazine | 7件: Ranolazine; Ranolazine 1000 mg; Ranolazine 1000 mg pr tablets; Ranolazine 500 mg; Ranolazine 500 mg pr tablets; Ranolazine 750 mg pr tablets; Ranolazine pr (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die; | D05700 D05701 |
- |
- |
6件: 2, 58, 86, 113, 114, 130 |
64 | Resveratrol | 1件: Resveratrol; | - |
- |
- |
3件: 8, 89, 113 |
65 | Rimeporide | 1件: Rimeporide; | - |
- |
- |
1件: 113 |
66 | Risedronic acid | 1件: Risedronic acid; | D00942 D03234 D08484 |
1件: FDPS |
4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
7件: 46, 66, 93, 95, 96, 113, 274 |
67 | Salbutamol | 5件: Nebulized combination ipratropium bromide with salbutamol; R-salbutamol; R-salbutamol sulphate; Salbutamol; Salbutamol 4mg tablet; | D02147 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
13件: 3, 11, 12, 13, 49, 85, 86, 89, 113, 228, 231, 256, 299 |
68 | Sildenafil | 25件: 20 mg sildenafil citrate by mouth; 5% sildenafil cream; Access program - sildenafil citrate, viagra, revatio; Acute (1 hour) sildenafil; Bosentan and sildenafil; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Oral sildenafil; Sildenafil; Sildenafil (50 mg); Sildenafil (as citrate); Sildenafil (revatio); Sildenafil (revatio) 20 mg tid; Sildenafil 20 mg tablets; Sildenafil 20mg; Sildenafil 20mg and bosentan 62.5mg; Sildenafil 40mg oral capsule; Sildenafil and losartan; Sildenafil citrate; Sildenafil citrate (uk-92,480); Sildenafil singly or in association with bosentan; Sildenafil therapy; Sitaxsentan and sildenafil; Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth; Sub-chronic (4 weeks) sildenafil; Tadalafil and sildenafil; | D02229 D08514 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
16件: 6, 46, 50, 51, 85, 86, 96, 113, 210, 211, 212, 225, 226, 278, 294, 299 |
69 | Somatotropin | 2件: Recombinant human somatotropin; Somatotropin; | D02691 |
1件: GHR |
5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
18件: 2, 3, 13, 19, 46, 74, 75, 78, 96, 113, 191, 193, 195, 236, 265, 274, 276, 299 |
70 | Spironolactone | 4件: Ambrisentan plus spironolactone; Spironolactone; Spironolactone and conivaptan; Spironolactone captopril carvedilol; | D00443 |
1件: NR3C2 |
1件: Aldosterone-regulated sodium reabsorption |
6件: 58, 67, 86, 113, 218, 225 |
71 | Tacrolimus | 13件: Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Interferon beta-1b and tacrolimus; Lcp-tacro (tacrolimus); Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Rectal tacrolimus; Tacrolimus; Tacrolimus (prograf®); Tacrolimus and mmf; Tacrolimus capsule; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus prolonged-release hard capsules; Tacrolimus with methotrexate; | D00107 D08556 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
30件: 2, 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 86, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 228, 283, 284, 299 |
72 | Tadalafil | 11件: Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Fdc macitentan/tadalafil; Tadalafil; Tadalafil 20 mg; Tadalafil 20 mg film-coated tablets; Tadalafil 40 mg; Tadalafil and ambrisentan upfront combination therapy; Tadalafil and sildenafil; Tadalafil oral suspension; Tadalafil, placebo; Tadalafil- tablet or oral suspension; | D02008 |
1件: PDE5A |
3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
6件: 6, 51, 75, 84, 86, 113 |
73 | Tamoxifen | 3件: Tamoxifen; Tamoxifen 40 mg daily for one year; Tamoxifen citrate; | D00966 D08559 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 2, 86, 113, 227 |
74 | Testosterone | 7件: Nebido® testosterone undecanoate 1000 mg/4 ml solution for injection; Sustanon (testosterone); Testosterone; Testosterone enanthate; Testosterone plus somatropin; Testosterone undecanoate; Transdermal testosterone gel; | D00075 D00957 D00958 D00959 D06085 D06087 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
7件: 1, 2, 3, 13, 78, 113, 265 |
75 | Testosterone enanthate | 1件: Testosterone enanthate; | D00958 |
1件: AR |
3件: Oocyte meiosis, Pathways in cancer, Prostate cancer |
1件: 113 |
76 | Tetracosactide | 4件: Tetracosactide; Tetracosactide acetate; Tetracosactide hexaacetate; Tetracosactide hexacetaat; | D00284 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
5件: 78, 83, 113, 145, 222 |
77 | Tideglusib | 1件: Tideglusib; | - |
- |
- |
2件: 5, 113 |
78 | Tranilast | 1件: Tranilast; | D02027 |
- |
- |
4件: 46, 84, 106, 113 |
79 | Trehalose | - | - |
- |
- |
1件: 113 |
80 | Ubidecarenone | - | D01065 |
- |
- |
12件: 2, 5, 6, 8, 10, 46, 57, 86, 113, 193, 214, 215 |
81 | Vamorolone | 9件: Vamorolone; Vamorolone 0.25 mg/day/day; Vamorolone 0.25 mg/kg/day; Vamorolone 0.75 mg/day/day; Vamorolone 0.75 mg/kg/day; Vamorolone 2.0 mg/day/day; Vamorolone 2.0 mg/kg/day; Vamorolone 6.0 mg/day/day; Vamorolone 6.0 mg/kg/day; | D11000 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 113 |
82 | Viltolarsen | 1件: Viltolarsen; | D11528 |
1件: DMD |
4件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Dilated cardiomyopathy (DCM), Hypertrophic cardiomyopathy (HCM), Viral myocarditis |
1件: 113 |
83 | rhIGFBP-3 | 3件: Rhigf-1/rhigfbp-3; Rhigf-i/rhigfbp-3; Rhigfbp-3; | - |
- |
- |
2件: 113, 195 |